Adenoviral delivery of a constitutively active retinoblastoma mutant inhibits neointima formation in a human explant model for vein graft disease

Vascular Pharmacology

Volumn 39, Issue 6, 2002, Pages 293-301

  Lamfers, Martine L M ^a   Aalders, Marjanka C ^a   Grimbergen, Jos M ^a   De Vries, Margreet R ^a   Kockx, Mark M ^b   Van Hinsbergh, Victor W M ^a,c   Quax, Paul H A ^a  

^a TNO   (Netherlands)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Adenoviral gene transfer; Coronary artery bypass graft; Intimal hyperplasia; Neointima formation

Indexed keywords

ADENOVIRUS VECTOR; TUMOR SUPPRESSOR PROTEIN;

ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE; VEIN DISEASE; VEIN GRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

EID: 0038309883     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(03)00043-0     Document Type: Article

References (49)

1. Asahara T., Bauters C., Zheng L.P., Takeshita S., Bunting S., Ferrara N., Symes J.F., Isner J.M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 92:1995;365-371.
2. Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:1998;82-89.
3. Burke S.E., Lubbers N.L., Chen Y.W., Hsieh G.C., Mollison K.W., Luly J.R., Wegner C.D. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J. Cardiovasc. Pharmacol. 33:1999;829-835.
4. Chang M.W., Barr E., Seltzer J., Jiang Y.Q., Nabel G.J., Nabel E.G., Parmacek M.S., Leiden J.M. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
5. Chen D., Krasinski K., Sylvester A., Chen J., Nisen P.D., Andres V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99:1997;2334-2341.
6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
7. Davies M.G., Hagen P.O. Pathobiology of intimal hyperplasia. Br. J. Surg. 81:1994;1254-1269.
8. Davies M.G., Hagen P.O. Structural and functional consequences of bypass grafting with autologous vein. Cryobiology. 31:1994;63-70.
9. Dilley R.J., McGeachie J.K., Prendergast F.J. A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia. Arch. Surg. 123:1988;691-696.
10. Engelse M.A., Lardenoye J.H.P., Neele J.M., Grimbergen J.M., de Vries M.R., Lamfers M.L.M., Pannekoek H., Quax P.H.A., de Vries C.J. Adenoviral activin a expression prevents intimal hyperplasia in human and murine blood vessels by maintaining the contractile smooth muscle cell phenotype. Circ. Res. 90:2002;1128-1134.
11. Gallo R., Padurean A., Jayaraman T., Marx S., Roque M., Adelman S., Chesebro J., Fallon J., Fuster V., Marks A., Badimon J.J. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:1999;2164-2170.
12. Goodrich D.W., Wang N.P., Qian Y.W., Lee E.Y., Lee W.H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. 67:1991;293-302.
13. Graham F.L., Prevec L. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:1995;207-220.
14. Guzman R.J., Hirschowitz E.A., Brody S.L., Crystal R.G., Epstein S.E., Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. U. S. A. 91:1994;10732-10736.
15. Hamel P.A., Gill R.M., Phillips R.A., Gallie B.L. Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene. Mol. Cell Biol. 12:1992;3431-3438.
16. Harrell R.L., Rajanayagam S., Doanes A.M., Guzman R.J. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 96:1997;621-627.
17. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., van Den Doel M.A., Vogels R., van Deutekom J., Janson A.A., de Bruijn J.D., Uytdehaag F., Quax P.H.A., Logtenberg T., Mehtali M., Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76:2002;4612-4620.
18. Huang H.J., Yee J.K., Shew J.Y., Chen P.L., Bookstein R., Friedmann T., Lee E.Y., Lee W.H. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science. 242:1988;1563-1566.
19. Kocan R.M., Moss N.S., Benditt E.P. Human arterial wall cells and tissues in culture. Methods Cell Biol. 21A:1980;153-166.
20. Kockx M.M., Cambier B.A., Bortier H.E., De Meyer G.R., Van Cauwelaert P.A. The modulation of smooth muscle cell phenotype is an early event in human aorto-coronary saphenous vein grafts. Virchows Arch. 420:1992;155-162.
21. Lamfers M.L.M., Wijnberg M.J., Grimbergen J.M., Huisman L.G., Aalders M.C., Cohen F.N., Verheijen J.H., van Hinsbergh V.W.M., Quax P.H.A. Adenoviral gene transfer of a u-PA receptor-binding plasmin inhibitor and green fluorescent protein: inhibition of migration and visualization of expression. Thromb. Haemost. 84:2000;460-467.
22. Lamfers M.L.M., Lardenoye J.H.P., de Vries M.R., Aalders M.C., Engelse M.A., Grimbergen J.M., van Hinsbergh V.W.M., Quax P.H.A. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Gene Ther. 8:2001;534-541.
23. Lamfers M.L.M., Grimbergen J.M., Aalders M.C., Havenga M.J., de Vries M.R., Huisman L.G., van Hinsbergh V.W.M., Quax P.H.A. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1. ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ. Res. 91:2002;945-952.
24. Luo Z.Y., Sata M., Nguyen T., Kaplan J.M., Akita G.Y., Walsh K. Adenovirus-mediated delivery of Fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 99:1999;1776-1779.
25. Mann M.J., Gibbons G.H., Tsao P.S., Vonderleyen H.E. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J. Clin. Invest. 99:1997;1295-1301.
26. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., Orav E.J., Ehsan A., Dellacqua G., Dzau V.J. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 354:1999;1493-1498.
27. Mannion J.D., Ormont M.L., Magno M.G., Obrien J.E., Shi Y., Zalewski A. Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Ann. Thorac. Surg. 66:1998;1948-1952.
28. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban H.E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:2002;1773-1780.
29. Ohno T., Gordon D., San H., Pompili V.J., Imperiale M.J., Nabel G.J., Nabel E.G. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265:1994;781-784.
30. Ookawa K., Shiseki M., Takahashi R., Yoshida Y., Terada M., Yokota J. Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene. 8:1993;2175-2181.
31. Porter K.E., Varty K., Jones L., Bell P.R., London N.J. Human saphenous vein organ culture: a useful model of intimal hyperplasia? Eur. J. Vasc. Endovasc. Surg. 11:1996;48-58.
32. Quax P.H.A., Lamfers M.L.M., Lardenoye J.H., Grimbergen J.M., de Vries M.R., Slomp J., de Ruiter M.C., Kockx M.M., Verheijen J.H., van Hinsbergh V.W.M. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation. 103:2001;562-569.
33. Scheinman M., Ascher E., Levi G.S., Hingorani A., Shirazian D., Seth P. p53 gene transfer to the injured rat carotid artery decreases neointimal formation. J. Vasc. Surg. 29:1999;360-369.
34. Schwartz L.B., Moawad J., Svensson E.C., Tufts R.L., Meyerson S.L., Baunoch D., Leiden J.M. Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J. Vasc. Surg. 29:1999;874-881.
35. Sherr C.J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
36. Shi Y., Obrien J.E., Fard A., Mannion J.D., Wang D. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 94:1996;1655-1664.
37. Slomp J., Gittenberger-deGroot A.C., van Munsteren J.C., Huysmans H.A., van Bockel J.H., van Hinsbergh V.W.M., Poelmann R.E. Nature and origin of the neointima in whole vessel wall organ culture of the human saphenous vein. Virchows Arch. 428:1996;59-67.
38. Smith R.C., Branellec D., Gorski D.H., Guo K., Perlman H. p21(CIP1)-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. 11:1997;1674-1689.
39. Smith R.C., Wills K.N., Antelman D., Perlman H., Truong L.N., Krasinski K., Walsh K. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation. 96:1997;1899-1905.
40. Sousa J.E., Costa M.A., Abizaid A.C., Rensing B.J., Abizaid A.S., Tanajura L.F., Kozuma K., Van Langenhove G., Sousa A.G., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 104:2001;2007-2011.
41. Soyombo A.A., Angelini G.D., Bryan A.J., Jasani B., Newby A.C. Intimal proliferation in an organ culture of human saphenous vein. Am. J. Pathol. 137:1990;1401-1410.
42. Spray T.L., Roberts W.C. Changes in saphenous veins used as aortocoronary bypass grafts. Am. Heart J. 94:1977;500-516.
43. Takahashi R., Hashimoto T., Xu H.J., Hu S.X., Matsui T., Miki T., Bigo-Marshall H., Aaronson S.A., Benedict W.F. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5257-5261.
44. Ueno H., Masuda S., Nishio S., Li J.J., Yamamoto H., Takeshita A. Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor-p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann. N. Y. Acad. Sci. 811:1997;401-411.
45. Ueno H., Yamamoto H., Ito S.I., Li J.J., Takeshita A. Adenovirus-mediated transfer of a dominant-negative h-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler. Thromb. Vasc. Biol. 17:1997;898-904.
46. Wang C.Y., Petryniak B., Thompson C.B., Kaelin W.G., Leiden J.M. Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science. 260:1993;1330-1335.
47. Westerband A., Mills J.L., Marek J.M., Heimark R.L., Hunter G.C., Williams S.K. Immunocytochemical determination of cell type and proliferation rate in human vein graft stenoses. J. Vasc. Surg. 25:1997;64-73.
48. Westerband A., Mills J.L., Hunter G.C., Gentile A.T., Ihnat D., Heimark R.L. Topography of cell replication in human vein graft stenoses. Circulation. 98:1998;II325-II329.
49. Yang Z.Y., Simari R.D., Perkins N.D., San H., Gordon D. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7905-7910.